Severity
Low
FDA Drug recall · Reported February 15, 2023
Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.
Akorn, Inc. recalled Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, 2 mL bo… - a low-severity action.
Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, 2 mL bo… was recalled by Akorn, Inc. in February 15, 2023. Reason: Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M st…. Check the official notice for the remedy. Verify recall #D-0265-2023 with the FDA Drug before acting.
The recall
Akorn, Inc. issued this low-severity FDA Drug recall-Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M st….
Sourced from official FDA Drug enforcement records. Verify recall #D-0265-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0265-2023) was formally reported on February 15, 2023, with the manufacturer initiating the action on January 30, 2023. It is classified under Low severity (Class III), with a current status of Ongoing. Akorn, Inc. is listed as the recalling firm, operating out of Gurnee, IL. Federal records list the affected scope as 45,117 Bottles.
The documented reason for this recall is: Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint. Distribution data in the federal record shows the product reached: Nationwide in the USA and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
45,117 Bottles
Related Recalls
6
5 from same agency
Atropine Sulfate Ophthalmic Solution, USP 1%, For Topical Application To The Eye, 2 mL bottle, Sterile, Rx only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. NDC: 17478-215-02
Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Ongoing |
| Recall number | D-0265-2023 |
| Date reported | February 15, 2023 |
| Date initiated | January 30, 2023 |
| Recalling firm | Akorn, Inc. |
| Firm location | Gurnee, IL |
| Affected scope | 45,117 Bottles |
| Distribution | Nationwide in the USA and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 15, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.